WEKO3
アイテム
{"_buckets": {"deposit": "5adf0de6-2bb1-4526-83bb-8aef80a89163"}, "_deposit": {"created_by": 1, "id": "70834", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "70834"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00070834", "sets": ["28"]}, "author_link": ["695975", "695968", "695974", "695971", "695969", "695970", "695976", "695973", "695967", "695972"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2012-07-21", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Purpose: To evaluate the value of hyperfractionated radiotherapy with concurrent use of low dose docetaxel in locally advanced head and neck cancer.\nMethods: Patients eligible for this study had confirmed diagnosis of squamous cell carcinoma stages II (\u003e10 m3), III, IVA and IVB of the head and neck. Radiotherapy was delivered twice a day at 1.2 Gy/fraction to a total dose of 72.0 Gy. Docetaxel (10 mg/m2) was administered weekly during radiotherapy.\nResults: From March 2003 to October 2008, 70 patients were treated. Primary sites included the oropharynx (n=25), hypopharynx (n=24), larynx (n=18), and other sites (n= 3). Stages II (n=11), III (n=16), IVA (n=33) were included. Major grade 3 acute toxicities included mucositis (n=42) and treatment related pain (n=12). The median follow-up period for surviving patients was 43 months. The 2-year local control rate and overall survival rate were 72.5% and 70.0%, respectively.\nConclusion: Hyperfractionated radiotherapy with concurrent docetaxel is a valuable treatment modality for the management of locally advanced head and neck cancer.", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "The 6th S. Takahashi Memorial Symposium \u0026 The 6th Japan-US Cancer Therapy International Joint Symposium", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Karasawa, Kumiko"}], "nameIdentifiers": [{"nameIdentifier": "695967", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsumoto, Fumihiko"}], "nameIdentifiers": [{"nameIdentifier": "695968", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ito, Shin"}], "nameIdentifiers": [{"nameIdentifier": "695969", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Oba, Shinichi"}], "nameIdentifiers": [{"nameIdentifier": "695970", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Furuya, Tomohisa"}], "nameIdentifiers": [{"nameIdentifier": "695971", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hirowatari, Hisako"}], "nameIdentifiers": [{"nameIdentifier": "695972", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Izawa, Hiromi"}], "nameIdentifiers": [{"nameIdentifier": "695973", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ito, Kana"}], "nameIdentifiers": [{"nameIdentifier": "695974", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sasai, Keisuke"}], "nameIdentifiers": [{"nameIdentifier": "695975", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "唐澤 久美子", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "695976", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "Hyperfractionated radiotherapy with concurrent docetaxel in advanced head and neck cancer: a phase II study", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Hyperfractionated radiotherapy with concurrent docetaxel in advanced head and neck cancer: a phase II study"}]}, "item_type_id": "10005", "owner": "1", "path": ["28"], "permalink_uri": "https://repo.qst.go.jp/records/70834", "pubdate": {"attribute_name": "公開日", "attribute_value": "2012-07-24"}, "publish_date": "2012-07-24", "publish_status": "0", "recid": "70834", "relation": {}, "relation_version_is_last": true, "title": ["Hyperfractionated radiotherapy with concurrent docetaxel in advanced head and neck cancer: a phase II study"], "weko_shared_id": -1}
Hyperfractionated radiotherapy with concurrent docetaxel in advanced head and neck cancer: a phase II study
https://repo.qst.go.jp/records/70834
https://repo.qst.go.jp/records/7083444197280-666d-4e44-bf3f-0f18e0a23c8a
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2012-07-24 | |||||
タイトル | ||||||
タイトル | Hyperfractionated radiotherapy with concurrent docetaxel in advanced head and neck cancer: a phase II study | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Karasawa, Kumiko
× Karasawa, Kumiko× Matsumoto, Fumihiko× Ito, Shin× Oba, Shinichi× Furuya, Tomohisa× Hirowatari, Hisako× Izawa, Hiromi× Ito, Kana× Sasai, Keisuke× 唐澤 久美子 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Purpose: To evaluate the value of hyperfractionated radiotherapy with concurrent use of low dose docetaxel in locally advanced head and neck cancer. Methods: Patients eligible for this study had confirmed diagnosis of squamous cell carcinoma stages II (>10 m3), III, IVA and IVB of the head and neck. Radiotherapy was delivered twice a day at 1.2 Gy/fraction to a total dose of 72.0 Gy. Docetaxel (10 mg/m2) was administered weekly during radiotherapy. Results: From March 2003 to October 2008, 70 patients were treated. Primary sites included the oropharynx (n=25), hypopharynx (n=24), larynx (n=18), and other sites (n= 3). Stages II (n=11), III (n=16), IVA (n=33) were included. Major grade 3 acute toxicities included mucositis (n=42) and treatment related pain (n=12). The median follow-up period for surviving patients was 43 months. The 2-year local control rate and overall survival rate were 72.5% and 70.0%, respectively. Conclusion: Hyperfractionated radiotherapy with concurrent docetaxel is a valuable treatment modality for the management of locally advanced head and neck cancer. |
|||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | The 6th S. Takahashi Memorial Symposium & The 6th Japan-US Cancer Therapy International Joint Symposium | |||||
発表年月日 | ||||||
日付 | 2012-07-21 | |||||
日付タイプ | Issued |